Voya Investment Management LLC lessened its stake in shares of Davita Inc (NYSE:DVA) by 4.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 71,386 shares of the company’s stock after selling 3,104 shares during the period. Voya Investment Management LLC’s holdings in Davita were worth $4,957,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. bought a new position in shares of Davita in the second quarter worth about $3,421,000. Tibra Equities Europe Ltd bought a new position in shares of Davita in the second quarter worth about $1,627,000. OppenheimerFunds Inc. boosted its stake in shares of Davita by 58.7% in the second quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock worth $282,365,000 after acquiring an additional 1,504,347 shares during the period. Alps Advisors Inc. boosted its stake in shares of Davita by 11.1% in the second quarter. Alps Advisors Inc. now owns 10,781 shares of the company’s stock worth $749,000 after acquiring an additional 1,080 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Davita by 3.0% in the second quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock worth $89,168,000 after acquiring an additional 37,362 shares during the period. 87.71% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on DVA. JPMorgan Chase & Co. raised Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Zacks Investment Research raised Davita from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. Finally, William Blair reaffirmed a “buy” rating on shares of Davita in a research note on Wednesday, June 6th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $82.13.
Davita (NYSE:DVA) last released its quarterly earnings data on Wednesday, August 1st. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. Davita had a return on equity of 14.49% and a net margin of 4.30%. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter in the prior year, the company posted $0.92 earnings per share. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. equities research analysts predict that Davita Inc will post 4 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Why do companies issue stock splits?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.